PMC:7039956 / 1416-4611 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

LitCovid-PD-UBERON

LitCovid-PD-HP

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":854,"end":856},"obj":"Chemical"},{"id":"T2","span":{"begin":904,"end":906},"obj":"Chemical"},{"id":"T3","span":{"begin":923,"end":925},"obj":"Chemical"},{"id":"T4","span":{"begin":1170,"end":1181},"obj":"Chemical"},{"id":"T5","span":{"begin":1200,"end":1202},"obj":"Chemical"},{"id":"T6","span":{"begin":1509,"end":1516},"obj":"Chemical"},{"id":"T7","span":{"begin":1561,"end":1570},"obj":"Chemical"},{"id":"T8","span":{"begin":2121,"end":2123},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_33382"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Introduction\nSince December 2019, an increasing number of patients with pneumonia occurred in Wuhan, Hubei province, China, which attracted much attention not only within China but across the world1,2. The novel pneumonia was named as Corona Virus Disease 19 (COVID-19) by World Health Organization (WHO) (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2), the common symptoms of COVID-19 at illness onset were fever, fatigue, dry cough, myalgia, and dyspnea3. In addition, some patients might suffer from headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting3. Onset of disease may lead to progressive respiratory failure due to alveolar damage and even death4.\nScientists then isolated a novel coronavirus from human airway epithelial cells, which was named 2019-nCoV5. Lu et al.6 found that 2019-nCoV was closer to bat-SL-CoVZC45 and bat-SL-CoVZXC21 at the whole-genome level, and the external subdomain of the 2019-nCoV receptor-binding domain (RBD) was more similar to that of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). Study of Zhou et al.4 indicated that the angiotensin-converting enzyme II (ACE2) is likely the cell receptor of 2019-nCoV, which were also the receptor for SARS-CoV and HCoV-NL637,8. Zhou et al.4 also proved that 2019-nCoV does not use other coronavirus receptors, aminopeptidase N, and dipeptidyl peptidase 4. The study of Xu et al.9 found that the RBD domain of the 2019-nCoV S-protein supports strong interaction with human ACE2 molecules. These findings suggest that the ACE2 plays an important role in cellular entry, thus ACE2-expressing cells may act as target cells and are susceptible to 2019-nCoV infection10.\nThe expression and distribution of the ACE2 in human body may indicate the potential infection routes of 2019-nCoV. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (AT2) of lung10–12, esophagus upper and stratified epithelial cells, absorptive enterocytes from ileum and colon12, cholangiocytes13, myocardial cells, kidney proximal tubule cells, and bladder urothelial cells10. These findings indicated that those organs with high ACE2-expressing cells should be considered as potential high risk for 2019-nCoV infection10.\nIn order to investigated the potential routes of 2019-nCov infection on the mucosa of oral cavity, we explored whether the ACE2 is expressed and the ACE2-expressing cell composition and proportion in oral cavity based on the public bulk RNA-seq profiles from two public databases and single-cell transcriptomes from an independent data generated in-house. The result showed that the ACE2 could be expressed in the oral cavity, and was highly enriched in epithelial cells. Moreover, among different oral sites, ACE2 expression was higher in tongue than buccal and gingival tissues. These findings indicate that the mucosa of oral cavity may be a potentially high risk route of 2019-nCov infection."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":0,"end":12},"obj":"Sentence"},{"id":"T11","span":{"begin":13,"end":201},"obj":"Sentence"},{"id":"T12","span":{"begin":202,"end":528},"obj":"Sentence"},{"id":"T13","span":{"begin":529,"end":643},"obj":"Sentence"},{"id":"T14","span":{"begin":644,"end":744},"obj":"Sentence"},{"id":"T15","span":{"begin":745,"end":853},"obj":"Sentence"},{"id":"T16","span":{"begin":854,"end":1128},"obj":"Sentence"},{"id":"T17","span":{"begin":1129,"end":1311},"obj":"Sentence"},{"id":"T18","span":{"begin":1312,"end":1439},"obj":"Sentence"},{"id":"T19","span":{"begin":1440,"end":1571},"obj":"Sentence"},{"id":"T20","span":{"begin":1572,"end":1748},"obj":"Sentence"},{"id":"T21","span":{"begin":1749,"end":1864},"obj":"Sentence"},{"id":"T22","span":{"begin":1865,"end":2076},"obj":"Sentence"},{"id":"T23","span":{"begin":2077,"end":2352},"obj":"Sentence"},{"id":"T24","span":{"begin":2353,"end":2498},"obj":"Sentence"},{"id":"T25","span":{"begin":2499,"end":2854},"obj":"Sentence"},{"id":"T26","span":{"begin":2855,"end":2970},"obj":"Sentence"},{"id":"T27","span":{"begin":2971,"end":3079},"obj":"Sentence"},{"id":"T28","span":{"begin":3080,"end":3195},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Introduction\nSince December 2019, an increasing number of patients with pneumonia occurred in Wuhan, Hubei province, China, which attracted much attention not only within China but across the world1,2. The novel pneumonia was named as Corona Virus Disease 19 (COVID-19) by World Health Organization (WHO) (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2), the common symptoms of COVID-19 at illness onset were fever, fatigue, dry cough, myalgia, and dyspnea3. In addition, some patients might suffer from headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting3. Onset of disease may lead to progressive respiratory failure due to alveolar damage and even death4.\nScientists then isolated a novel coronavirus from human airway epithelial cells, which was named 2019-nCoV5. Lu et al.6 found that 2019-nCoV was closer to bat-SL-CoVZC45 and bat-SL-CoVZXC21 at the whole-genome level, and the external subdomain of the 2019-nCoV receptor-binding domain (RBD) was more similar to that of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). Study of Zhou et al.4 indicated that the angiotensin-converting enzyme II (ACE2) is likely the cell receptor of 2019-nCoV, which were also the receptor for SARS-CoV and HCoV-NL637,8. Zhou et al.4 also proved that 2019-nCoV does not use other coronavirus receptors, aminopeptidase N, and dipeptidyl peptidase 4. The study of Xu et al.9 found that the RBD domain of the 2019-nCoV S-protein supports strong interaction with human ACE2 molecules. These findings suggest that the ACE2 plays an important role in cellular entry, thus ACE2-expressing cells may act as target cells and are susceptible to 2019-nCoV infection10.\nThe expression and distribution of the ACE2 in human body may indicate the potential infection routes of 2019-nCoV. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (AT2) of lung10–12, esophagus upper and stratified epithelial cells, absorptive enterocytes from ileum and colon12, cholangiocytes13, myocardial cells, kidney proximal tubule cells, and bladder urothelial cells10. These findings indicated that those organs with high ACE2-expressing cells should be considered as potential high risk for 2019-nCoV infection10.\nIn order to investigated the potential routes of 2019-nCov infection on the mucosa of oral cavity, we explored whether the ACE2 is expressed and the ACE2-expressing cell composition and proportion in oral cavity based on the public bulk RNA-seq profiles from two public databases and single-cell transcriptomes from an independent data generated in-house. The result showed that the ACE2 could be expressed in the oral cavity, and was highly enriched in epithelial cells. Moreover, among different oral sites, ACE2 expression was higher in tongue than buccal and gingival tissues. These findings indicate that the mucosa of oral cavity may be a potentially high risk route of 2019-nCov infection."}

2_test

{"project":"2_test","denotations":[{"id":"32094336-31986257-53457423","span":{"begin":197,"end":198},"obj":"31986257"},{"id":"32094336-23329690-53457424","span":{"begin":199,"end":200},"obj":"23329690"},{"id":"32094336-32365354-53457425","span":{"begin":742,"end":743},"obj":"32365354"},{"id":"32094336-32334705-53457426","span":{"begin":863,"end":864},"obj":"32334705"},{"id":"32094336-32365354-53457427","span":{"begin":1149,"end":1150},"obj":"32365354"},{"id":"32094336-14647384-53457428","span":{"begin":1305,"end":1308},"obj":"14647384"},{"id":"32094336-15897467-53457429","span":{"begin":1309,"end":1310},"obj":"15897467"},{"id":"32094336-32365354-53457430","span":{"begin":1323,"end":1324},"obj":"32365354"},{"id":"32094336-32318909-53457431","span":{"begin":1462,"end":1463},"obj":"32318909"},{"id":"T41652","span":{"begin":197,"end":198},"obj":"31986257"},{"id":"T61985","span":{"begin":199,"end":200},"obj":"23329690"},{"id":"T2908","span":{"begin":742,"end":743},"obj":"32365354"},{"id":"T24209","span":{"begin":863,"end":864},"obj":"32334705"},{"id":"T45122","span":{"begin":1149,"end":1150},"obj":"32365354"},{"id":"T45703","span":{"begin":1305,"end":1308},"obj":"14647384"},{"id":"T29939","span":{"begin":1309,"end":1310},"obj":"15897467"},{"id":"T46737","span":{"begin":1323,"end":1324},"obj":"32365354"},{"id":"T74693","span":{"begin":1462,"end":1463},"obj":"32318909"}],"text":"Introduction\nSince December 2019, an increasing number of patients with pneumonia occurred in Wuhan, Hubei province, China, which attracted much attention not only within China but across the world1,2. The novel pneumonia was named as Corona Virus Disease 19 (COVID-19) by World Health Organization (WHO) (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2), the common symptoms of COVID-19 at illness onset were fever, fatigue, dry cough, myalgia, and dyspnea3. In addition, some patients might suffer from headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting3. Onset of disease may lead to progressive respiratory failure due to alveolar damage and even death4.\nScientists then isolated a novel coronavirus from human airway epithelial cells, which was named 2019-nCoV5. Lu et al.6 found that 2019-nCoV was closer to bat-SL-CoVZC45 and bat-SL-CoVZXC21 at the whole-genome level, and the external subdomain of the 2019-nCoV receptor-binding domain (RBD) was more similar to that of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV). Study of Zhou et al.4 indicated that the angiotensin-converting enzyme II (ACE2) is likely the cell receptor of 2019-nCoV, which were also the receptor for SARS-CoV and HCoV-NL637,8. Zhou et al.4 also proved that 2019-nCoV does not use other coronavirus receptors, aminopeptidase N, and dipeptidyl peptidase 4. The study of Xu et al.9 found that the RBD domain of the 2019-nCoV S-protein supports strong interaction with human ACE2 molecules. These findings suggest that the ACE2 plays an important role in cellular entry, thus ACE2-expressing cells may act as target cells and are susceptible to 2019-nCoV infection10.\nThe expression and distribution of the ACE2 in human body may indicate the potential infection routes of 2019-nCoV. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (AT2) of lung10–12, esophagus upper and stratified epithelial cells, absorptive enterocytes from ileum and colon12, cholangiocytes13, myocardial cells, kidney proximal tubule cells, and bladder urothelial cells10. These findings indicated that those organs with high ACE2-expressing cells should be considered as potential high risk for 2019-nCoV infection10.\nIn order to investigated the potential routes of 2019-nCov infection on the mucosa of oral cavity, we explored whether the ACE2 is expressed and the ACE2-expressing cell composition and proportion in oral cavity based on the public bulk RNA-seq profiles from two public databases and single-cell transcriptomes from an independent data generated in-house. The result showed that the ACE2 could be expressed in the oral cavity, and was highly enriched in epithelial cells. Moreover, among different oral sites, ACE2 expression was higher in tongue than buccal and gingival tissues. These findings indicate that the mucosa of oral cavity may be a potentially high risk route of 2019-nCov infection."}

PMC:7039956 / 1416-4611 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7039956 / 1416-4611 JSON TXT